You are here: Industry Insights > EU

News List

EU nod for Vertex CF therapy Kaftrio pharmatimes
August 24, 2020
Vertex Pharmaceuticals' Kaftrio (ivacaftor/tezacaftor/elexacaftor) has been approved by the European Commission for use in combination with ivacaftor to treat people aged 12 years and older with certain forms of cystic fibrosis.
CureVac and EU Discuss Advanced Purchase Agreement contractpharma
August 21, 2020
CureVac, a clinical-stage biopharmaceutical company, and the European Commission have concluded exploratory talks outlining an Advanced Purchase Agreement (APA) for CureVac’s potential mRNA-based COVID-19 vaccine.
EU, CureVac may sign deal for 225 million doses of COVID-19 vaccine expresspharma
August 21, 2020
CureVac said it could start large-scale human trials on its vaccine in the last quarter of this year based on results of its current trials.
EU approves new indication for Novartis’ Xolair pharmatimes
August 07, 2020
The European Commission has approved a new indication for Novartis’ Xolair (omalizumab) as an add-on therapy for the treatment of adults with sever chronic rhinosinusitis with nasal polyps (CRSwNP).
EU regulators approve Novartis' breast cancer combo pharmatimes
July 31, 2020
European regulators have approved Novartis' Piqray (alpelisib) in combination with fulvestrant for the treatment of a certain type of breast cancer.
Eleven medicines backed for EU approval pharmatimes
July 27, 2020
The European Medicines Agency human medicines committee (CHMP) has backed eleven medicines for approval at its July 2020 meeting, including a medicine for use in countries outside the region and a novel treatment for multiple myeloma.
EU raises its bet on blood plasma in search for COVID-19 therapy expresspharma
July 13, 2020
The move also highlights the more assertive approach being taken by the 27-nation union in the race to find effective drugs and vaccines against the new coronavirus.
EU secures potential COVID-19 drugs from Roche, Germany’s Merck – source expresspharma
July 10, 2020
The deals cover Roche’s arthritis drug RoActemra and Merck’s multiple sclerosis drug Rebif - both seen as potential COVID-19 therapies - and will secure supplies for any of the 27 European Union member states wanting to buy them.
EU nod for Lynparza in pancreatic cancer pharmatimes
July 09, 2020
AstraZeneca and MSD's Lynparza (olaparib) has been approved in the EU for patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer.
CureVac nets EU funding to ramp up vaccine production expresspharma
July 07, 2020
CureVac, backed by the Bill & Melinda Gates Foundation, is a pioneer in the so-called messenger RNA approach, which is also being pursued by BioNTech and its partner Pfizer as well as Moderna.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page